I don’t subscribe to Barron’s so I got as far as here:
“Would people get the jabs every year, like they do for influenza, or would the process be more like that for GSK’s shingles vaccine, which is good for at least seven years?”
GSK’s RSV vaccine is already definitely not annual based on season 2 data. The question is biennial or even triennial based on season 3 data. (The studies were designed to randomize through 3 seasons no more). GSK doesn’t think efficacy will hold up through 3 seasons and is obviously hoping if that’s the case biennial dosing offers more protection in year 3. On the off chance year 3 data has reasonable efficacy I would expect them to charge more for the vaccine just like they did when the season 2 data came in and they went to ACIP with a much higher cost than initially proposed.
Shingrix data has held up now through 10 years so not sure where the 7 years came from in this Barron’s piece (maybe for very very old I haven’t seen the data broken down by age )
Market Data 
Markets 
AI
